article thumbnail

COVID-19 Vaccine Safe for Children Who Had Previous MIS-C Diagnosis

Drug Topics

Patients with a history of multisystem inflammatory syndrome in children (MIS-C) completed a questionnaire about adverse reactions following COVID-19 vaccination, and no serious adverse events were recorded.

article thumbnail

Common Adverse Reactions to EGFR Therapy

Pharmacy Times

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Managing Adverse Events Associated with HE Therapies

Pharmacy Times

Riello, PharmD, BCPS, discusses the adverse events associated with hepatic encephalopathy (HE) treatments and the importance of encouraging patients to continue first-line medications despite adverse reactions to prevent HE recurrence.

article thumbnail

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Pharmacy Times

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. OLC, a lanthanum-based phosphate binder, showed efficacy and tolerability in a phase 2 trial, with most patients achieving target serum phosphate levels.

65
article thumbnail

Therapeutic-first for cold agglutinin disease haemolytic anaemia

European Pharmaceutical Review

The study found 96 percent of patients who recieved Enjaymo ® and all participants in the placebo group experienced at least one treatment emergent adverse event (TEAE). Serious adverse reactions (SARs) were reported in 13 percent (3/24) of patients who received the mAb. Headache (22.7 percent vs 10.0

article thumbnail

FDA approves first treatment for geographic atrophy

European Pharmaceutical Review

A milestone for retinal ophthalmology The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade.” It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.

FDA 98
article thumbnail

Does rosuvastatin cause hair loss?

The Checkup by Singlecare

of all rosuvastatin reactions. Here’s the raw data behind those numbers: According to the FDA Adverse Events Reporting System (FAERS), alopecia represents 789 out of 49,963 rosuvastatin reactions , or 1.6%. The American Academy of Cardiology says 10–15% of people who take statins develop an adverse reaction.

52